Barry Allen Joins Orpyx Medical Technologies Inc. Board of Directors as Director and Executive Chairman
Calgary, AB, Canada, February 15, 2019 – Mr. Barry Allen was recently named Executive Chairman of Orpyx Medical Technologies’ Board of Directors. Mr. Allen is CEO and President of PureWeb Inc. and Founder and Chairman or Zolo Canada.
In addition to his current role at PureWeb Inc., Mr. Allen is an Associate for the Creative Destruction Labs in Calgary and Vancouver. From 1998 to 2004, he was President and CEO of VSM MedTech. During his tenure, the company grew from two to almost 250 employees and evolved from an R&D company to a world class manufacturer and marketer of high-tech medical devices with sales of approximately $20 million in 2003. Mr. Allen raised in excess of $65 million in capital for VSM and led the Company’s migration from the TSX Venture Exchange to the TSX with a market cap of almost $400 million.
As Executive Chairman, Mr. Allen will provide valuable guidance to the Orpyx team. He brings both the expertise and vision to Orpyx, advancing the company’s agenda of disrupting digital diabetes management. His experience across a number of the medical technology organizations, and as an advisor to successful start-ups, will provide invaluable support to Orpyx’s scaling up of operations.
About Orpyx Medical Technologies Inc.
Founded in 2010, Orpyx Medical Technologies empowers people with diabetes to maintain mobility. Orpyx’s core product line, the SurroSense® intelligent insole systems, help manage and prevent diabetic foot ulcers and limb loss through FDA cleared, advanced foot sensor technology and analytics. Orpyx’s technology is used by researchers to access clinical-grade plantar pressure measurement data for health and human performance applications. Orpyx is focused on collaborating with stakeholders around the world to achieve a healthcare future that is prevention focused and sustainable in cost. Learn more at www.orpyx.com.
For more information, please contact:
Chan Chong
Marketing Manager, Orpyx Medical Technologies Inc.
chan.chong@orpyx.com
+1 403 460 0216 ext. 501
Orpyx secures $20M investment led by Perceptive Advisors
Siksika Health Services and Partners Expand Pilot Program to Enhance Foot Health and Prevent Diabetic Foot Ulcers Among Siksika Nation Members
Siksika Health Services, Orpyx, and GMAK Consulting Collaborate to Help Eliminate Foot Complications for Patients with Type 2 Diabetes through the PATHWAYS Indigenous Health Collaborations Program
